UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000056804 |
|---|---|
| Receipt number | R000064923 |
| Scientific Title | Survey on the Intake of Oral Nutritional Supplements in Cancer Patients |
| Date of disclosure of the study information | 2025/02/01 |
| Last modified on | 2025/04/09 11:01:29 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Survey on the Intake of Oral Nutritional Supplements in Cancer Patients
Acronym
Survey on the Intake of Oral Nutritional Supplements in Cancer Patients
Scientific Title
Survey on the Intake of Oral Nutritional Supplements in Cancer Patients
Scientific Title:Acronym
Survey on the Intake of Oral Nutritional Supplements in Cancer Patients
Region
| Japan |
Condition
Condition
Cancer Patients
Classification by specialty
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To deepen the understanding of the oral nutritional supplements required by cancer patients, and to assist in product development and appropriate product usage.
Basic objectives2
Others
Basic objectives -Others
None
Trial characteristics_1
Others
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. Background of the Study Participants (Age, Gender, Type of Cancer, Cancer Treatment, Presence of Appetite or Taste Disorders, and Oral Mucositis)
2. Feedback on Product A (Taste, Texture, Ease of Consumption, Intent to Continue Intake, and Willingness to Recommend to Others)
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Persons diagnosed with cancer
2. Aged 20 years or older
3. Those who have consumed Product A
4. Those who fully understand the research content and have provided voluntary consent to participate in this study
5. Capable of independently answering the survey
Key exclusion criteria
None
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Yukikazu |
| Middle name | |
| Last name | Kamada |
Organization
Nestle Japan Ltd
Division name
Nestle Health Science Company
Zip code
140-0002
Address
Tennozu Ocean Square 20F, 2-2-20 Higashi-Shinagawa, Shinagawa-ku, Tokyo
TEL
070-2278-7597
Yukikazu.Kamada@jp.nestle.com
Public contact
Name of contact person
| 1st name | Hiroki |
| Middle name | |
| Last name | Takano |
Organization
Nestle Japan Ltd
Division name
Nestle Health Science Company
Zip code
140-0002
Address
Tennozu Ocean Square 20F, 2-2-20 Higashi-Shinagawa, Shinagawa-ku, Tokyo
TEL
070-2448-5234
Homepage URL
Hiroki.Takano@jp.nestle.com
Sponsor or person
Institute
Nestle Japan Ltd
Institute
Department
Personal name
Funding Source
Organization
Nestle Japan Ltd
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Shiba Palace Clinic Ethics Review Committee
Address
DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN
Tel
03-5408-1599
shiba_palace@s-palace-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2025 | Year | 01 | Month | 21 | Day |
Date of IRB
| 2025 | Year | 01 | Month | 23 | Day |
Anticipated trial start date
| 2025 | Year | 02 | Month | 02 | Day |
Last follow-up date
| 2026 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
None
Management information
Registered date
| 2025 | Year | 01 | Month | 24 | Day |
Last modified on
| 2025 | Year | 04 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064923
